Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Brad S Kahl, MD, John M. Burke, MD, Richard van der Jagt, MD FRCPC, Julie Chang, MD, Peter Wood, Tim Hawkins, FRACP, FRCPA, David MacDonald, Judith Trotman, MBChB, FRACP, FRCPA, David Simpson, MBChB, Kathryn S. Kolibaba, MD, Samar Issa, FRACP, Doreen Hallman, Ling Chen, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 484.

https://doi.org/10.1182/blood.V130.Suppl_1.484.484

Published: 2017

Journal Articles

Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study

Richard van der Jagt, MD FRCPC, Caroline Hamm, MD FRCPC, Isabelle Fleury, MD MSc, FRCP, Véronique Lambert-Obry, M.Sc., Avril Gouault Laliberté, MSc, Alex Castonguay, M.Sc., Dennis Wagner, PhD, Lisa Toltl, PhD, Jean Lachaine, PhD

Blood (2017) 130 (Supplement 1): 5632.

https://doi.org/10.1182/blood.V130.Suppl_1.5632.5632

Published: 2017

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

Journal Articles

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

Kenneth B. Miller, MD, Haesook T. Kim, PhD, Peter Greenberg, MD, Richard van der Jagt, MD, John M. Bennett, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD, Gordon Dewald, PhD, Jessie G. Houston, MD, Mary Thomas, RN, MS, Jacob Rowe, MD

Blood (2004) 104 (11): 70.

https://doi.org/10.1182/blood.V104.11.70.70

Published: 2004

Journal Articles

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Jonathan Friedberg, MD, Philip Cohen, MD, Robert O. Kerr, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Richard van der Jagt, MD, Elber Camacho, MD, John Hainsworth, MD, Brent Roeck, Pratik S. Multani, MD

Blood (2004) 104 (11): 2480.

https://doi.org/10.1182/blood.V104.11.2480.2480

Published: 2004

NARROW

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only